These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Mucus structure and properties in cystic fibrosis. Rubin BK Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972 [TBL] [Abstract][Full Text] [Related]
30. Inhaled hypertonic saline as a therapy for cystic fibrosis. Elkins MR; Bye PT Curr Opin Pulm Med; 2006 Nov; 12(6):445-52. PubMed ID: 17053496 [TBL] [Abstract][Full Text] [Related]
31. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. Suri R BioDrugs; 2005; 19(3):135-44. PubMed ID: 15984899 [TBL] [Abstract][Full Text] [Related]
32. The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology. Hardy CL; King SJ; Mifsud NA; Hedger MP; Phillips DJ; Mackay F; de Kretser DM; Wilson JW; Rolland JM; O'Hehir RE Immunol Cell Biol; 2015 Jul; 93(6):567-74. PubMed ID: 25753271 [TBL] [Abstract][Full Text] [Related]
33. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. App EM; King M; Helfesrieder R; Köhler D; Matthys H Am Rev Respir Dis; 1990 Mar; 141(3):605-12. PubMed ID: 2310093 [TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Boucher RC Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805 [TBL] [Abstract][Full Text] [Related]
36. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa]. Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155 [TBL] [Abstract][Full Text] [Related]
37. New aerosol delivery devices for cystic fibrosis. Kesser KC; Geller DE Respir Care; 2009 Jun; 54(6):754-67; discussion 767-8. PubMed ID: 19467162 [TBL] [Abstract][Full Text] [Related]
38. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Gehrig S; Duerr J; Weitnauer M; Wagner CJ; Graeber SY; Schatterny J; Hirtz S; Belaaouaj A; Dalpke AH; Schultz C; Mall MA Am J Respir Crit Care Med; 2014 May; 189(9):1082-92. PubMed ID: 24678594 [TBL] [Abstract][Full Text] [Related]
39. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis. Knowles MR; Olivier K; Noone P; Boucher RC Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S65-9. PubMed ID: 7533608 [TBL] [Abstract][Full Text] [Related]
40. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME Respiration; 2001; 68(2):160-4. PubMed ID: 11287830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]